Lexaria Bioscience Corp.
LEXX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001348362
No open-market purchases or sales by Lexaria Bioscience Corp. insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $920.0K in total; no superinvestor holds it.
13F holders, Q2 2024
Institutional positions in Lexaria Bioscience Corp. as of Jun 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 28
- +3 vs. Q1 2024
- Shares held
- 2.06M
- +1.17M (+131.5%) vs. Q1 2024
- Total value
- $5.72M
- +$2.49M (+77.3%) vs. Q1 2024
- New holders
- 4
- 10 more added
- Sold out
- 1
- 3 more reduced
Compare with Q1 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting LEXX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 31 | $920.0K |
| Q1 2026 | 28 | $1.17M |
| Q4 2025 | 21 | $1.05M |
| Q3 2025 | 25 | $1.63M |
| Q2 2025 | 21 | $2.00M |
| Q1 2025 | 22 | $2.12M |
| Q4 2024 | 25 | $3.03M |
| Q3 2024 | 27 | $3.25M |
| Q2 2024 | 28 | $5.72M |
| Q1 2024 | 25 | $3.23M |
| Q4 2023 | 20 | $1.49M |
| Q3 2023 | 15 | $1.77M |
| Q2 2023 | 14 | $651.4K |
| Q1 2023 | 17 | $1.85M |
| Q4 2022 | 16 | $1.71M |
| Q3 2022 | 16 | $1.68M |
| Q2 2022 | 16 | $1.67M |
| Q1 2022 | 12 | $1.41M |
| Q4 2021 | 13 | $1.85M |
| Q3 2021 | 11 | $2.83M |
| Q2 2021 | 10 | $2.93M |
| Q1 2021 | 9 | $1.78M |
Institutions, Q2 2024
Shares, value and share of portfolio for each institution holding Lexaria Bioscience Corp.; share changes are against Q1 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Toronto Dominion Bank | 13 | $36 | 0.00% | 00.0% | Unchanged |
| Gables Capital Management Inc. | 13 | $36 | 0.00% | 00.0% | Unchanged |
| Allworth Financial LP | 89 | $243 | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 96 | $267 | 0.00% | −141−59.5% | Reduced |
| Mather Group, LLC. | 100 | $363 | 0.00% | +100 | New |
| Farther Finance Advisors, LLC | 166 | $458 | 0.00% | 00.0% | Unchanged |
| Aspire Private Capital, LLC | 400 | $1.11K | 0.00% | 00.0% | Unchanged |
| ADAR1 Capital Management, LLC | 945 | $2.63K | 0.00% | −25,681−96.5% | Reduced |
| Advisor Group Holdings, Inc. | 2,290 | $6.37K | 0.00% | +100+4.6% | Added |
| 1832 Asset Management L.P. | 2,686 | $7.47K | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 3,300 | $9.17K | 0.00% | +2,227+207.5% | Added |
| Tower Research Capital LLC (TRC) | 3,370 | $9.37K | 0.00% | +668+24.7% | Added |
| Oakworth Capital, Inc. | 5,000 | $13.9K | 0.00% | 00.0% | Unchanged |
| Royal Bank of Canada | 7,283 | $20.0K | 0.00% | 00.0% | Unchanged |
| XTX Topco Ltd | 12,602 | $35.0K | 0.00% | +2,326+22.6% | Added |
| Wealth Enhancement Advisory Services, LLC | 13,823 | $38.4K | 0.00% | +3,500+33.9% | Added |
| Northern Trust Corp | 18,389 | $51.1K | 0.00% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 22,800 | $63.4K | 0.00% | +22,800 | New |
| Morgan Stanley | 22,982 | $63.9K | 0.00% | −372−1.6% | Reduced |
| Welch Group, LLC | 24,000 | $66.7K | 0.00% | 00.0% | Unchanged |
| BlackRock Inc. | 27,445 | $76.3K | 0.00% | +25,937+1,720.0% | Added |
| State Street Corp | 39,301 | $109.3K | 0.00% | 00.0% | Unchanged |
| Raymond James Financial Services Advisors, Inc. | 48,800 | $135.7K | 0.00% | +9,250+23.4% | Added |
| GenTrust, LLC | 60,000 | $166.8K | 0.01% | +60,000 | New |
| Vanguard Group Inc | 93,586 | $260.2K | 0.00% | +8,430+9.9% | Added |
| Geode Capital Management, LLC | 114,783 | $319.2K | 0.00% | +15,445+15.5% | Added |
| Invenomic Capital Management LP | 513,573 | $1.43M | 0.07% | +40,308+8.5% | Added |
| Armistice Capital, LLC | 1,020,000 | $2.84M | 0.07% | +1,020,000 | New |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −15,856−100.0% | Sold out |